Back to results
US 8,026,250 B2Granted
Compositions for delivering highly water soluble drugs
AssigneeAdventrx Pharmaceuticals, Inc.
InventorAndrew Xian Chen
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.
Claims12
A method for treating breast cancer, said method comprising:
- administering to a patient in need thereof a composition, wherein said composition comprises
- vinorelbine bitartrate in an oil-in-water emulsion having an oil phase and an aqueous phase, wherein the oil phase comprises a triglyceride oil having medium chain fatty acids, soy lecithin, and oleic acid, and the aqueous phase comprises water, sucrose, and disodium edetate (EDTA) dihydrate, wherein in excess of 80% of the vinorelbine bitartrate is dissolved and remains in the oil phase,
- and wherein:
- (a) vinorelbine bitartrate is at a concentration of 1.4% (w/w);
- (b) triglyceride oil having medium chain fatty acids is at a concentration of 15% (w/w);
- (c) soy lecithin is at a concentration of 7.5% (w/w);
- (d) oleic acid is at a concentration of 1.5% (w/w);
- (e) sucrose is at a concentration of 15% (w/w);
- (f) disodium edetate (EDTA) dihydrate is at a concentration of 0.005% (w/w);
- (g) vinorelbine bitartrate to oleic acid is in a 1:4 molar ratio;
- (h) the composition is at a pH of 3.7;
- and
- (i) water to q.s., thereby treating breast cancer.
10 more elements
A method for treating non-small cell lung cancer, said method comprising:
- administering to a patient in need thereof a composition, wherein said composition comprises:
- vinorelbine bitartrate in an oil-in-water emulsion having an oil phase and an aqueous phase, wherein the oil phase comprises a triglyceride oil having medium chain fatty acids, soy lecithin, and oleic acid, and the aqueous phase comprises water, sucrose, and disodium edetate (EDTA) dihydrate, wherein in excess of 80% of the vinorelbine bitartrate is dissolved and remains in the oil phase,
- and wherein:
- (a) vinorelbine bitartrate is at a concentration of 1.4% (w/w);
- (b) triglyceride oil having medium chain fatty acids is at a concentration of 15% (w/w);
- (c) soy lecithin is at a concentration of 7.5% (w/w);
- (d) oleic acid is at a concentration of 1.5% (w/w);
- (e) sucrose is at a concentration of 15% (w/w);
- (f) disodium edetate (EDTA) dihydrate is at a concentration of 0.005% (w/w);
- (g) vinorelbine bitartrate to oleic acid is in a 1:4 molar ratio;
- (h) the composition is at a pH of 3.7;
- and
- (i) water to q.s., thereby treating non-small cell lung cancer.
10 more elements
Dependencies are inferred from the claim text.